- Legend Biotech ( NASDAQ: LEGN ) received a notice from Nasdaq for not being in compliance with the exchange's listing rules as the company failed to file an interim balance sheet and income statement for the quarter ended June 30, 2022 on Form 6-K with the Securities and Exchange Commission (SEC).
- The company said it was required to file the Form 6-K by Dec. 31, 2022.
- Legend added that it has not yet filed the Form 6-K. This delay has resulted from the company's planned restatement of its financial statements as of and for the years ended Dec. 31, 2021, Dec. 31, 2020 and Dec. 31, 2019 and interim financial information for the three months ended March 31, 2022, as previously reported by the company on Oct. 20, 2022.
- The company added that the notice has no immediate effect on the listing of its American Depositary Shares and it has 60 days from the date of the notice or until March 7, 2023, to submit a proposal to regain compliance with the rules.
For further details see:
Legend Biotech gets Nasdaq non-compliance notice